drugset
drugset / Trial / NCT05491525

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

NCT05491525 ↗

Phase 2/3 Recruiting 71 enrolled Urovant Sciences GmbH Sumitomo Pharma America, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

Timeline

Start
2022-10-12
Primary completion
2030-03
Completion
2030-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Vibegron Unknown — Oral

Indications

overactive bladder